Metachromatic Leukodystrophy (MLD) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Metachromatic Leukodystrophy (MLD) - Pipeline Review, H1 2016

Metachromatic Leukodystrophy (MLD) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Metachromatic Leukodystrophy (MLD) - Pipeline Review, H1 2016
Published May 31, 2016
38 pages — Published May 31, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Metachromatic Leukodystrophy (MLD) - Pipeline Review, H1 2016, provides an overview of the Metachromatic Leukodystrophy (MLD) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Metachromatic Leukodystrophy (MLD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metachromatic Leukodystrophy (MLD) and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Metachromatic Leukodystrophy (MLD)
- The report reviews pipeline therapeutics for Metachromatic Leukodystrophy (MLD) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Metachromatic Leukodystrophy (MLD) therapeutics and enlists all their major and minor projects
- The report assesses Metachromatic Leukodystrophy (MLD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Metachromatic Leukodystrophy (MLD)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Metachromatic Leukodystrophy (MLD)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most

  
Source:
Document ID
GMDHC8151IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Metachromatic Leukodystrophy (MLD) Overview61
Therapeutics Development72
  Pipeline Products for Metachromatic Leukodystrophy (MLD) Overview71
  Pipeline Products for Metachromatic Leukodystrophy (MLD) Comparative Analysis81
Metachromatic Leukodystrophy (MLD) Therapeutics under Development by Companies91
Metachromatic Leukodystrophy (MLD) Therapeutics under Investigation by Universities/Institutes101
Metachromatic Leukodystrophy (MLD) Pipeline Products Glance112
  Clinical Stage Products111
  Early Stage Products121
Metachromatic Leukodystrophy (MLD) Products under Development by Companies131
Metachromatic Leukodystrophy (MLD) Products under Investigation by Universities/Institutes141
Metachromatic Leukodystrophy (MLD) Companies Involved in Therapeutics Development154
  ArmaGen Inc.151
  GlaxoSmithKline Plc161
  RegenxBio Inc.171
  Shire Plc181
Metachromatic Leukodystrophy (MLD) Therapeutics Assessment198
  Assessment by Monotherapy Products191
  Assessment by Target201
  Assessment by Mechanism of Action212
  Assessment by Route of Administration232
  Assessment by Molecule Type252
Drug Profiles277
  AGT-183 - Drug Profile271
    Product Description271
    Mechanism of Action271
    R&D Progress272
  Gene Therapy to Activate Arylsulfatase A for Metachromatic Leukodystrophy - Drug Profile291
    Product Description291
    Mechanism of Action291
    R&D Progress292
  GSK-2696274 - Drug Profile311
    Product Description311
    Mechanism of Action311
    R&D Progress311
  SHP-611 - Drug Profile321
    Product Description321
    Mechanism of Action321
    R&D Progress321
  Stem Cell Therapy to Activate Arylsulfatase A and ABCD1 for Metachromatic Leukodystrophy and Adrenoleukodystrophy - Drug Profile331
    Product Description331
    Mechanism of Action331
    R&D Progress331
Metachromatic Leukodystrophy (MLD) Recent Pipeline Updates341
Metachromatic Leukodystrophy (MLD) - Dormant Projects351
Metachromatic Leukodystrophy (MLD) Discontinued Products361
Appendix372
  Methodology371
  Coverage371
  Secondary Research371
  Primary Research371
  Expert Panel Validation371
  Contact Us371
  Disclaimer381

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Metachromatic Leukodystrophy (MLD) - Pipeline Review, H1 2016" May 31, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Metachromatic-Leukodystrophy-MLD-Pipeline-Review-H1-2016-2088-15902>
  
APA:
Global Markets Direct - Market Research. (2016). Metachromatic Leukodystrophy (MLD) - Pipeline Review, H1 2016 May 31, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Metachromatic-Leukodystrophy-MLD-Pipeline-Review-H1-2016-2088-15902>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.